Want to see FR:NANO full AI Analyst Report?

Nanobiotix (NANO) Price & Analysis

34 Followers

NANO Stock Chart & Stats

€35.24

-€0.84(-2.38%)

At close: Jul 28 4:00 PM EDT

€35.24

-€0.84(-2.38%)

Day’s Range― - ―

52-Week Range€6.21 - €47.66

Previous CloseN/A

Volume28.17K

Average Volume (3M)654.19K

Market Cap

€1.69B

Enterprise Value€986.13

Total Cash (Recent Filing)€52.75M

Total Debt (Recent Filing)€95.32M

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Sep 30, 2026

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding50,619,583

10 Day Avg. Volume711,483

30 Day Avg. Volume654,186

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)-10.94

Price to Sales (P/S)31.19

P/FCF Ratio-27.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€55.00

Price Target Upside56.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.21

Revenue Forecast (FY)€34.90M

Bulls Say, Bears Say

Bulls Say

Proprietary Platform And Strategic PartnershipA partnership with Janssen provides durable clinical and commercial validation, access to partner R&D and regulatory resources, and milestone/royalty upside. This reduces program execution risk and supports non-dilutive funding pathways over the medium term.

High Gross Margin PotentialA reported 100% gross margin in 2025 signals that the nanoparticle therapeutic has the potential for scalable, high-margin revenue when commercialized or licensed. High product-level margins support long-term profitability once fixed development and SG&A costs normalize.

Oncology Focus With Immuno-radiotherapy MechanismTargeting radiotherapy enhancement with potential immune stimulation aligns with persistent oncology and immuno-oncology demand. A platform enabling combination therapy positions the company for durable partner interest and multiple development pathways across tumor types.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow erodes runway and forces reliance on external financing. Over months this elevates dilution or refinancing risk and constrains the company's ability to independently fund pivotal trials or commercialization investments.

Negative Shareholders' Equity And Rising DebtNegative equity combined with increasing debt materially weakens financial flexibility and raises leverage risk. This structural capital weakness increases cost of capital and vulnerability to covenant or refinancing stress over the medium term.

Volatile, Inconsistent Revenue And Ongoing LossesHighly variable revenue and persistent net losses mean earnings are not yet repeatable. Lumpy, milestone-driven income undermines predictability of cash flow and complicates planning, keeping sustainable profitability uncertain over the coming quarters.

Nanobiotix News

Nanobiotix Updates Market on Share Capital and Voting Rights Structure

Nanobiotix ( ($FR:NANO) ) just unveiled an announcement. Nanobiotix reported that as of June 30, 2026, it had...

12d ago

Nanobiotix Reaffirmed at Buy on Strengthened Balance Sheet and Strategic Shift Toward Nanoprimer Platform Growth

Stifel Nicolaus analyst Clémence Thiers reiterated a Buy rating on Nanobiotix today and set a price target of...

3M ago

NBTX

Nanobiotix falls -9.0%

Nanobiotix (NBTX) is down -9.0%, or -$3.88 to $39.28. Published first on TheFly – the ultimate source for...

3M ago

NBTX

Nanobiotix announces EUR 75M global follow-on offering

Nanobiotix (NBTX) announces the launch, subject to market and other conditions, of an approximately EUR 75M global follow-on...

3M ago

NBTX

Nanobiotix files EUR75M ordinary shares offering

16:23 EDT Nanobiotix (NBTX) files EUR75M ordinary shares offering Published first on TheFly – the ultimate source for...

3M ago

NBTX

Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 60 from EUR 34 and keeps...

3M ago

NBTX

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

Nanobiotix (NBTX) announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study. This protocol amendment,...

3M ago

JNJ

NBTX

Nanobiotix price target raised to $30 from $3.50 at UBS

UBS raised the firm’s price target on Nanobiotix (NBTX) to $30 from $3.50 and keeps a Neutral rating...

3M ago

NBTX

Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix and keeping the price target at...

4M ago

NBTX

Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 34 from EUR...

4M ago

NBTX

Nanobiotix Earnings Call: Deeper J&J Ties, Lower Loss

Nanobiotix SA (($FR:NANO)) has held its Q4 earnings call. Read on for the main highlights of the call....

4M ago

Nanobiotix price target raised to $36 from $26 at Guggenheim

Guggenheim raised the firm’s price target on Nanobiotix (NBTX) to $36 from $26 and keeps a Buy rating...

4M ago

NBTX

Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile

TD Cowen analyst Tara Bancroft has maintained their bullish stance on NBTX stock, giving a Buy rating today....

4M ago

NBTX

Nanobiotix price target raised to $37 from $26 at Leerink

Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $37 from $26 and keeps...

4M ago

NBTX

NANO FAQ

What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest stock price was €6.21 and its highest was €47.66 in the past 12 months.

What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €1.69B.

When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 50 days.

How were Nanobiotix SA’s earnings last quarter?

Currently, no data Available

Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix SA pay dividends?

Nanobiotix SA does not currently pay dividends.

What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate is -0.25.

How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 50,619,583 shares outstanding.

What happened to Nanobiotix SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in FR:NANO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanobiotix SA

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Nanobiotix (NANO) Earnings & Revenues

Historic Earnings Reports

NANO Stock 12 Month Forecast

Average Price Target

€55.00

▲(56.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","61":"€61","18.25":"€18.25","32.5":"€32.5","46.75":"€46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.25,32.5,46.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.72,35.74153846153846,37.76307692307692,39.784615384615385,41.80615384615385,43.82769230769231,45.84923076923077,47.87076923076923,49.892307692307696,51.91384615384615,53.93538461538462,55.956923076923076,57.97846153846154,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.72,35.356923076923074,36.99384615384615,38.63076923076923,40.26769230769231,41.90461538461538,43.54153846153846,45.178461538461534,46.815384615384616,48.45230769230769,50.08923076923077,51.72615384615385,53.36307692307692,{"y":55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.72,34.58769230769231,35.45538461538462,36.323076923076925,37.19076923076923,38.058461538461536,38.926153846153845,39.793846153846154,40.66153846153846,41.52923076923077,42.39692307692307,43.26461538461538,44.13230769230769,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.88,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.26,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >